Centre Hospitalier Intercommunal
- Address
- Saint Aubin-lès-Elbeuf, 76503 Elbeuf, France
Centre Hospitalier Intercommunal - Oncology Research
The Centre Hospitalier Intercommunal is engaged in advanced oncology research with a focus on thoracic malignancies. The center participates in Phase III clinical trials investigating innovative adjuvant immunotherapy approaches for surgically treated lung cancer patients, demonstrating expertise in post-operative cancer management and translational research.
- Non-small cell lung cancer (NSCLC) adjuvant therapy studies
- PD-L1 targeted immunotherapy research
- Post-surgical oncologic treatment optimization in early to locally advanced stage disease
The center's research portfolio emphasizes precision oncology through biomarker-driven patient selection, particularly focusing on PD-L1 expression profiling and molecular characterization including EGFR and ALK mutation status. This approach ensures participation in cutting-edge therapeutic strategies for completely resected stage IB-IIIA lung cancer patients, contributing to the advancement of personalized treatment paradigms in thoracic oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Intercommunal
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25% | Clinipace Global Limited, Fundacion GECP, Intergroupe Francophone De Cancerologie Thoracique, NVALT-studies Stichting, Queen's University | Phase III | Not Recruiting | Mar 2015 | Mar 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Durvalumab | 1 | Unknown | 2015-03-09 | 2015-03-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.